Breaking News: Dr. Gabor Maté, recognised physician and bestselling author, joins Numinus as Member of the Clinical Advisory Council | Financial Buzz

Breaking News: Dr. Gabor Maté, recognised physician and bestselling author, joins Numinus as Member of the Clinical Advisory Council

Numinus Wellness Inc. (TSX-V: NUMI) is pleased to announce the appointment of Dr. Gabor Maté, MD, CM, as a Member of the Numinus Clinical Advisory Council. Through over 30 years’ work in family practice, palliative care and addiction medicine, Dr. Maté has pioneered therapies and innovative, trauma-based approaches to mental health. His advocacy for mental health research and awareness have earned him international recognition from the healthcare community.

“We at Numinus are extremely honoured and excited to have someone with Gabor’s pedigree and on-the-ground experience,” says Numinus CEO Payton Nyquvest. “Gabor offers exceptional insight on the mental health landscape and its future, which greatly complements our goals and mission at Numinus.”

As a Member of the Clinical Advisory Council, Dr. Maté will be a vital resource in helping Numinus develop treatments and drive policy changes within the healthcare industry. Additionally, Dr. Maté will also use his network to enhance Numinus’s collaboration with other leading researchers and groups working in mental illness, addiction and trauma treatment.

“Gabor is a well-respected clinician with a wealth of knowledge on the links between trauma and mental health, as well as ways to promote healing,” says Dr. Evan Wood, Chief Medical Officer of Numinus. “He has been on the forefront of innovative mental health strategies for many years and I look forward to collaborating with him to advance the Numinus model.”

Dr. Maté is internationally recognised for his expertise in addiction, trauma, childhood development, and the link between stress and illness. Beyond his work as a medical practitioner, he is a sought-after speaker and bestselling author with reprints in over 25 languages. His book on addiction received the Hubert Evans Prize for literary non-fiction. For his groundbreaking medical work and writing, he has been awarded the Order of CanadaCanada’s highest civilian distinction, and the Civic Merit Award from his hometown of Vancouver, B.C.

As part of his effort to broaden public awareness of mental illness and contribute to the local community, Dr. Maté spent over a decade working in Vancouver’s Downtown Eastside caring for patients facing severe addiction and mental health challenges. Dr. Maté continues to push boundaries and identify new pathways for healing and advancement in mental health.

About Numinus

Numinus is a Vancouver-based health care company helping to support the universal desire to heal and be well. Through its wholly-owned subsidiary Salvation Botanicals, Numinus has a Health Canada cannabis testing licence that allows the company to test and analyze cannabis products from licensed producers. In addition, it is a late-stage applicant to receive a Health Canada standard processing licence to produce cannabis products. Numinus, through the same subsidiary, also has a dealer’s licence which allows the company to test, possess, buy and sell MDMA, psilocybin, psilocin, DMT and mescaline. It is seeking to expand the licence to include activities such as import/export, testing and R&D. The expanded licence will allow Numinus to support the growing number of studies on the potential benefits of psychedelic therapies through research projects, product development, and the supply and distribution of these substances. Numinus Wellness is dedicated to therapies that enhance and supplement existing options for people wanting lasting physical, mental and emotional health — with psychedelic treatments at its core when approved for therapeutic and research use. Psychedelics will be part of this offering but will only be available for treatment once approved by regulators and governing bodies — a process Numinus is helping to support. 

Sponsored Content Release. Click for Full Disclosure

  • Sponsored Content Release, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR branding, marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For numinus wellness inc., financial and corporate news dissemination, has been compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: